Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone

Breast Cancer Research

Volumn 8, Issue 2, 2006, Pages

  Sloan, Erica K ^a,c   Pouliot, Normand ^a   Stanley, Kym L ^a   Chia, Jenny ^a   Moseley, Jane M ^b   Hards, Daphne K ^b   Anderson, Robin L ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; MATRIX PROTEIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MATRIX; BONE METASTASIS; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG METASTASIS; MAMMARY GLAND; MOUSE; MOUSE STRAIN; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPINE METASTASIS; TIBIA; TUMOR PROMOTION; TUMOR VOLUME; ANIMAL; BONE TUMOR; BREAST TUMOR; CELL DIVISION; CELL LINE; CYTOLOGY; HUMAN; METASTASIS; PATHOLOGY; PHYSIOLOGY; SECONDARY; SPINAL CORD TUMOR; UDDER;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE; EPITHELIAL CELLS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MAMMARY GLANDS, ANIMAL; MICE; NEOPLASM METASTASIS; SPINAL NEOPLASMS;

EID: 33746513396     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1398     Document Type: Article

References (61)

1. Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998, 77:336-340.
2. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55:61-66.
3. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032.
4. Hewitt RE, Powe DG, Morrell K, Balley E, Leach IH, Ellis IO, Turner DR: Laminin and collagen IV subunit distribution in normal and neoplastic tissues of colorectum and breast. Br J Cancer 1997, 75:221-229.
5. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B: Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:9482-9487.
6. Zutter MM, Sun H, Santoro SA: Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia 1998, 3:191-200.
7. Liapis H, Flath A, Kitazawa S: Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996, 5:127-135.
8. Cooper CR, Chay CH, Pienta KJ: The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002, 4:191-194.
9. Eliceiri BP, Cheresh DA: Adhesion events in angiogenesis. Curr Opin Cell Biol 2001, 13:563-568.
10. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
11. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822.
12. Varner JA, Nakada MT, Jordan RE, Coller BS: Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 1999, 3:53-60.
13. Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RO: Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci USA 2004, 101:763-768.
14. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM: Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001, 98:1853-1858.
15. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN: Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003, 100:14205-14210.
16. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM: Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997, 71:320-324.
17. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA: Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998, 4:2625-2634.
18. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M: Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20:413-420.
19. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001, 98:119-124.
20. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, Markland FS: Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 2000, 61:249-260.
21. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8:27-34.
22. Tucker GC: Inhibitors of integrins. Curr Opin Pharmacol 2002, 2:394-402.
23. Pignatelli M, Cardillo MR, Hanby A, Stamp GW: Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992, 23:1159-1166.
24. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD: Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993, 53:1421-1430.
25. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC, Smith JW: Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 1998, 16:50-61.
26. van der P, Vloedgraven H, Papapoulos S, Lowick C, Grzesik W, Kerr J, Robey PG: Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997, 77:665-675.
27. Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW: Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998, 176:482-494.
28. Noti JD: Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 2000, 17:1237-1243.
29. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY: Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000, 86:15-23.
30. Bartsch JE, Staren ED, Appert HE: Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res 2003, 110:287-294.
31. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001, 263:209-223.
32. Gomes N, Vassy J, Lebos C, Arbeille B, Legrand C, Fauvel-Lafeve F: Breast adenocarcinoma cell adhesion to the vascular sub-endothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists. Clin Exp Metastasis 2004, 21:553-561.
33. Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO: Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res 2004, 64:2751-2758.
34. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF, Tuck AB: Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003, 1:810-819.
35. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 2004, 64:977-984.
36. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M: Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002, 19:427-436.
37. Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Westlin M, Schroeter S, Ruminski PG, Griggs DW: Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 2004, 21:129-138.
38. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, et al.: Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. Faseb J 2002, 16:1266-1268.
39. Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, et al.: A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004, 21:119-128.
40. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL: Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005, 3:1-13.
41. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, et al.: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999, 17:163-170.
42. Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52:1399-1405.
43. Morgenstern JP, Land H: A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990, 18:1068.
44. Pouliot N, Saunders NA, Kaur P: Laminin 10/11: an alternative adhesive ligand for epidermal keratinocytes with a functional role in promoting proliferation and migration. Exp Dermatol 2002, 11:387-397.
45. Sloan EK, Anderson RL: Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 2002, 59:1491-1502.
46. Kakonen SM, Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834-839.
47. Tester AM, Ruangpanit N, Anderson RL, Thompson EW: MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 2000, 18:553-560.
48. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M: The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 2005, 25:79-83.
49. Kitazawa S, Maeda S: Development of skeletal metastases. Clin Orthop Relat Res 1995, 312:45-50.
50. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G, Pantel K: Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999, 59:241-248.
51. Baciu PC, Suleiman EA, Deryugina EI, Strongin AY: Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res 2003, 291:167-175.
52. Deryugina EI, Ratnikov BI, Strongin AY: Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer 2003, 104:533-541.
53. Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY: Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002, 277:9749-9756.
54. David Roodman G: Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003, 97:733-738.
55. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
56. Doerr ME, Jones JI: The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996, 271:2443-2447.
57. Borges E, Jan Y, Ruoslahti E: Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 2000, 275:39867-39873.
58. Schneller M, Vuori K, Ruoslahti E: Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 1997, 16:5600-5607.
59. Woodard AS, Garcia-Cardena G, Leong M, Madri JA, Sessa WC, Languino LR: The synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration. J Cell Sci 1998, 111:469-478.
60. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE: Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 2005, 11:306-314.
61. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725.